News
Sanofi and Bristol-Myers Squibb Announce Restructuring of Alliance Agreement
Sanofi and Bristol-Myers Squibb Company have restructured their successful long-term alliance following the loss of exclusivity of Plavix and Avapro/Avalide in many major markets. Under the terms of the revised agreement, which will go...
News
New antibiotic cures disease by disarming pathogens
A new type of antibiotic can effectively treat an antibiotic-resistant infection by disarming instead of killing the bacteria that cause it. Researchers report their findings in the October 2 issue of mBio®, the online open-access journal of the...
News
Biological markers increase clinical trial success rate of new breast cancer drugs
Using biological markers - genetic characteristics that are associated with some patients with breast cancer - can increase the success rate of clinical trials for breast cancer drugs by almost 50 per cent, says new research from the...
News
Bayer’s Stivarga® (regorafenib) tablets approved by FDA for treatment of metastatic colorectal cancer
Bayer HealthCare announced that the U.S. Food and Drug Administration (FDA) approved Stivarga® (regorafenib) tablets for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with currently available therapies (including fluoropyrimidine-, oxaliplatin- and...
News
Roche leads healthcare sector in key sustainability index for fourth consecutive year
Roche has been recognised as the most sustainable healthcare company globally in the Dow Jones Sustainability Index (DJSI), for the fourth year in a row. The DJSI World and DJSI Europe Indexes track the performance of...
News
First efficacy results for dengue vaccine candidate
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced the online publication in The Lancet of clinical study results showing the ability of its vaccine candidate to protect against dengue fever caused by three...
News
Bayer HealthCare starts special lab space-model CoLaborator™ for promising life science companies
Bayer HealthCare officially opened its new life sciences hub for early stage research companies, dubbed the "CoLaborator™", in San Francisco's Mission Bay. The CoLaborator™-approach is to support start-ups in establishing their research labs, with academic researchers spinning out...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.